Presentation of Interim Results

AI SummaryClose X

Genflow Biosciences Plc announced interim results from its SLAB-VET-001 study of SIRT6c gene therapy in aged dogs, presenting at the Animal Longevity Summit. The therapy was generally well tolerated with no serious adverse events. At Day 182, the two plasmid DNA (pDNA) arms showed the largest mean reductions in DNA-methylation age, with the low-dose pDNA arm reducing epigenetic age by -1.08 years compared to -0.07 years in the control group, and 10 of 12 pDNA-treated dogs showed a lower epigenetic age. Preliminary muscle biopsy histology indicated preserved muscle structure and regeneration in treated dogs, with muscle mass increasing significantly in the high-dose pDNA and AAV8 arms by Day 259. IV pDNA has been selected as the lead delivery modality for the veterinary program, and the study's in-life phase has been extended for further epigenetic clock readings.

Disclaimer*

UK 100

Latest directors dealings